ONTX - Onconova Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue5,54611,456800
Cost of Revenue---
Gross Profit5,54611,456800
Operating Expenses
Research Development20,07125,89549,425
Selling General and Administrative9,1789,53315,119
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-23,703-23,972-63,744
Income from Continuing Operations
Total Other Income/Expenses Net4,050-35-32
Earnings Before Interest and Taxes-19,653-24,007-63,776
Interest Expense---
Income Before Tax-19,653-24,007-63,776
Income Tax Expense141619
Minority Interest830830874
Net Income From Continuing Ops-19,667-23,979-63,682
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-19,667-23,979-63,682
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-19,667-23,979-63,682